Erythropoietin--from gene structure to therapeutic applications.
All forms of oxygen deprivation act as a stimulus for the production of the hormone erythropoietin. The main sites of production are specialized renal fibroblasts in adult mammals and hepatic cells in mammalian fetuses and neonates. The hormone's name is a succint description of its main effect: erythropoietin stimulates red cell production from bone marrow precursors and hence controls the O2-carrying capacity of the blood. The peripheral red cell count is kept constant by a closely controlled feedback mechanism involving O2 supply, erythropoietin secretion and erythropoiesis; the system may become unbalanced in conditions such as chronic renal disease, chronic inflammation and prematurity. Recombinant human erythropoietin is used as hormonal replacement therapy to correct various types of anemia and replenish the red cell count following hemorrhage or blood donation for autologous transfusion.
Bauer
C
C
Physiology Department, Zurich-Irchel University, Switzerland.
D000740:Anemia / Q000188:drug therapy; D000818:Animals; D004921:Erythropoietin / Q000096:biosynthesis / Q000235:genetics / Q000627:therapeutic use; D006801:Humans; D000860:Hypoxia / Q000378:metabolism; D011994:Recombinant Proteins / Q000627:therapeutic use
D011994:Recombinant Proteins; D004921:Erythropoietin